Antioxidative and Immunomodulatory Effects of A-Lipoic Acid in Rat Colitis Model Induced by Acetic Acid

Authors

  • Bilal Ergül
  • Zeynal Doğan
  • Murat Sarıkaya
  • Levent Filik
  • Özlem Gül Utku
  • Mehmet Alpaslan Gönültaş
  • Sema Hücümenoğlu
  • Berrak Güven
  • Murat Can

Abstract

Aim: Benefit of α-Lipoic acid (ALA) was previously shown in rat-colitis model via suppression of neutrophil accumulation, preservation of endogenous glutathione and inhibition of reactive oxidant generation. Ulcerative colitis is a chronic inflammatory condition of the colon and cytokines (such as TNF-α, IL-1β and TGF-β) are crucial components of these inflammatory pathways. Hence, the present study was undertaken to evaluate the antioxidative and immunomodulatory effects of ALA on experimental colitis model induced by acetic acid in Wistar albino rats. Methods: Mice received either a control diet or ALA-supplemented diet for 14 d. Colitis was induced by acetic acid administration at 7th day. Mucosal damage and the activation of immune cells and cytokines were determined by macroscopic score, histological score, tissue cytokine levels (TNF-α, IL-1β and TGF-β). Anti-oxidant effect of ALA was determined by Malondialdehyde, and total antioxidative status. Results: Disease activity Index was significantly higher in colitis group compared to control, ALA and ALA-colitis groups (p<0.001). No significant difference was found between DAI of control, ALA and ALA-colitis groups. The inflammatory mediators, TNF-α and IL-1β, and MDA were elevated in colitis group compared to other groups (p<0.001, p<0.001 respectively). TGF-β and total antioxidative status were significantly lower in colitis group (p<0.001). Conclusion: ALA may possibly have some therapeutic usefulness in the management of ulcerative colitis.

References

Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 2011;11:9–20.

Strober, W., Ludviksson, B.R., Fuss, I.J., The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn's disease. Ann. Intern. Med. 1998;128, 848–56.

Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annual Review of Medicine.2000;51:289–98

Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16.

Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al . European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1–23.

Reed L. From lipoic acid to multi-enzyme complexes. Protein Sci.1998; 7: 220–4

Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001;17:888e95.

Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149-60.

Packer L, Roy S, Sen CK: Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997; 38: 79–101.

Biewenga GP, Haenen GR, Bast A: The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997; 29: 315–31.

Bilska, A., Włodek, L., Lipoic acid – the drug of the future. Pharmacol. Rep. 2005;57, 570–7.

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365-70.

Vasdev S, Gill V, Longerich L, Parai S, Gadag V. Salt-induced hypertension in WKY rats: prevention by alpha-lipoic acid supplementation. Mol Cell Biochem. 2003;254:319–26.

Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats. J Comp Physiol. 2004;174:587–92.

Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor- deficient mice. Circulation. 2008;117:421–8.

Zulkhairi A, Zaiton Z, Jamaluddin M, Sharida F, Mohd TH, Hasnah B, et al. Alpha lipoic acid possess dual antioxidant and lipid lowering properties in atherosclerotic-induced New Zealand white rabbit. Biomed Pharmacother. 2008;62:716–22.

Yang RL, Li W, Shi YH, Le GW. Lipoic acid prevents high-fat diet-induced dyslipidemia and oxidative stress: a microarray analysis. Nutrition. 2008;24:582–8.

Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens). 2006;5:251–8.

de Oliveira AM, Rondó PH, Luzia LA, D’Abronzo FH, Illison VK: The effects of lipoic acid and alpha-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res Clin Pract 2011; 92: 253– 60.

Min AK, Kim MK, Seo HY, Kim HS, Jang BK, Hwang JS, et al. Alpha-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-beta signaling pathway. Biochem Biophys Res Commun. 2010;393:536-41.

Ying Z, Kampfrath T, Sun Q, Parthasarathy S, Rajagopalan S. Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function. Inflamm Res. 2011;60:219-25.

Cooper HS, Murthy SN, Shah RS, Sedergran DJ Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69:238-49.

Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989; 96:795-803.

Appleyard CB and Wallace JL. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol 1995;269: G119–G125.

Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K, Kubben FJ, et al. Tissue level, activation and cellular localisation of TGF-b1 and association with survival in gastric cancer patients. British Journal of Cancer.2007; 97:398-404.

Lowry OH, Rosebrough NJ, Farr A, Randall RJ. Protein measurement with the folin phenol reagent. J. Biol. Chem.1951;193:265-75.

Gorąca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B. Lipoic acid - biological activity and therapeutic potential.Pharmacol Rep. 2011;63:849-58.

Kolgazi M, Jahovic N, Yüksel M, Ercan F, Alican I. Alpha-lipoic acid modulates gut inflammation induced by trinitrobenzene sulfonic acid in rats. J Gastroenterol Hepatol. 2007;22:1859-65.

Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–40

Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7:16-26.

Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96:822-8.

Cuzzocrea S, McDonald MC, Mazzon E, Mota-Filipe H, Centorrino T, Terranova ML, et al. Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. Gut. 2001;48:478–8.

Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med. 2002;33:311-22.

Loguercio C, D'Argenio G, Delle Cave M, Cosenza V, Della Valle N, Mazzacca G et al. Direct evidence of oxidative damage in acute and chronic phases of experimental colitis in rats. Dig Dis Sci. 1996;41:1204-11.

Emin O, Hasan A, Aysegul D, Rusen D. Total Antioxidant Status and Oxidative Stress and Their Relationship to Total IgE Levels and Eosinophil Counts in Children With Allergic Rhinitis J Investig Allergol Clin Immunol 2012;22: 188-192

Surekha RH, Srikanth BB, Jharna P, Ramachandra RV, Dayasagar RV, Jyothy A. Oxidative stress and total antioxidant status in myocardial infarction. Singapore Med J. 2007;48:137-42.

Valabhji J, McColl AJ, Richmond W, Schachter M, Rubens MB, Elkeles RS. Total antioxidant status and coronary artery calcification in type 1 diabetes. Diabetes Care. 2001;24:1608-13.

Downloads

Published

25.03.2019

Issue

Section

Original Research